We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.12 | -2.60% | 41.97 | 40.00 | 44.31 | 43.76 | 41.93 | 43.54 | 1,375,102 | 05:00:12 |
From May 2019 to May 2024
Isis Pharmaceuticals Inc. received regulatory clearance Friday for its partnership with AstraZeneca, by which the companies will develop antisense drugs for cardiovascular, metabolic and renal diseases.
Carlsbad, Calif.-based Isis will receive a $65 million upfront payment from AstraZeneca and is eligible for milestone payments during the development process in addition to royalties on potential sales.
The two companies have teamed up before and are in collaboration on several cancer drugs.
Isis has 38 drugs in its pipeline, and partners with Biogen Inc. and Sanofi's Genzyme, among others. The company specializes in RNA-targeted technology to develop antisense drugs. Antisense treatments are small, DNA- or RNA-like compounds that are chemically modified to create drugs.
Separately on Friday, AstraZeneca said it bought a Boulder, Colo., manufacturing facility from Amgen Inc. to support its growing pipeline.
Terms of the deal weren't disclosed and AstraZeneca said the acquisition doesn't affect its 2015 guidance. The site is expected to be operational and licensed for commercial production by late 2017, the company said.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 11, 2015 08:15 ET (12:15 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
